Assignee

BIOGEN INC

US125 patents

Top patents by PatentIndex Score

US4956288ASep 11, 1990

Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA

BIOGEN INC225 citations99

US4873316AOct 10, 1989

Isolation of exogenous recombinant proteins from the milk of transgenic mammals

BIOGEN INC1,295 citations99

US7112665B1Sep 26, 2006

Genetically engineered plant cells and plants exhibiting resistance to glutamine synthetase inhibitors, DNA fragments and recombinants for use in the production of said cells and plants

BIOGEN INC371 citations98

US6602503B1Aug 5, 2003

Recombinant anti-VLA-4 antibody molecules

BIOGEN INC183 citations98

US6162432ADec 19, 2000

Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction

BIOGEN INC159 citations98

US5804604ASep 8, 1998

Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease

BIOGEN INC78 citations97

US6669941B1Dec 30, 2003

Soluble lymphotoxin-β receptor as a therapeutic agent for treating TH-1 cell-associated autoimmune disease

BIOGEN INC42 citations96

US6482409B1Nov 19, 2002

Treatment for inflammatory bowel disease with a vcam-1/1gG fusion protein

BIOGEN INC48 citations96

US6403087B1Jun 11, 2002

Soluble lymphotoxin-β receptors as therapeutic agents for the treatment of immunological disease

BIOGEN INC52 citations96

US5888507AMar 30, 1999

Treatment for insulin dependent diabetes

BIOGEN INC87 citations96

US5871734AFeb 16, 1999

Treatment for asthma with VLA-4 blocking agents

BIOGEN INC58 citations96

US5256559AOct 26, 1993

Methods and compositions for inhibiting platelet aggregation

BIOGEN INC66 citations96

US5223394AJun 29, 1993

Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence

BIOGEN INC63 citations96

US5219990AJun 15, 1993

Papillomavirus e2 trans-activation repressors

BIOGEN INC37 citations96

US5547853AAug 20, 1996

CD2-binding domain of lymphocyte function associated antigen 3

BIOGEN INC66 citations95

US5217870AJun 8, 1993

Monoclonal antibodies against CDX

BIOGEN INC48 citations95

US5168049ADec 1, 1992

Production of streptavidin-like polypeptides

BIOGEN INC95 citations95

US5109124AApr 28, 1992

Nucleic acid probe linked to a label having a terminal cysteine

BIOGEN INC906 citations95

US6861509B1Mar 1, 2005

Antibodies to Ret and RetL3

BIOGEN INC43 citations94

US6664385B1Dec 16, 2003

Kidney injury-related molecules

BIOGEN INC88 citations94

US6252043B1Jun 26, 2001

Vascular cell adhesion molecule (VCAM) polypeptides

BIOGEN INC47 citations94

US5545723AAug 13, 1996

Muteins of IFN-β

BIOGEN INC60 citations94

US5367056ANov 22, 1994

Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules involved in leukocyte adhesion (MILAs)

BIOGEN INC50 citations94

US5272263ADec 21, 1993

DNA sequences encoding vascular cell adhesion molecules (VCAMS)

BIOGEN INC72 citations94

US5196404AMar 23, 1993

Inhibitors of thrombin

BIOGEN INC84 citations94

US5487984AJan 30, 1996

Processes for producing tumor necrosis factor

BIOGEN INC58 citations93

US5240913AAug 31, 1993

Inhibitors of thrombin

BIOGEN INC50 citations93

US7255854B1Aug 14, 2007

Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases

BIOGEN INC21 citations92

US6764681B2Jul 20, 2004

Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction

BIOGEN INC39 citations92

US6627202B2Sep 30, 2003

HBV core antigen particles with multiple immunogenic components attached via peptide ligands

BIOGEN INC25 citations92

US6376538B1Apr 23, 2002

Cell adhesion inhibitors

BIOGEN INC26 citations92

US6323027B1Nov 27, 2001

Common gamma chain monoclonal antibody blocking agents

BIOGEN INC39 citations92

US6306840B1Oct 23, 2001

Cell adhesion inhibitors

BIOGEN INC38 citations92

US5928643AJul 27, 1999

Method of using CD2-binding domain of lymphocyte function associated antigen 3 to initiate T cell activation

BIOGEN INC24 citations92

US5914111AJun 22, 1999

CD2-binding domain of lymphocyte function associated antigen-3

BIOGEN INC30 citations92

US5871732AFeb 16, 1999

Anti-CD4 antibody homologs useful in prophylaxis and treatment of AIDS, ARC and HIV infection

BIOGEN INC68 citations92

US5795964AAug 18, 1998

Lymphotoxin-beta and lymphotoxin-beta complexes

BIOGEN INC37 citations92

US5728677AMar 17, 1998

Methods of inhibiting T-cell dependent proliferation of peripheral blood lymphocytes using the CD2-binding domain of lymphocyte function associated antigen 3

BIOGEN INC20 citations92

US5670149ASep 23, 1997

Lymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof

BIOGEN INC38 citations92

US5667965ASep 16, 1997

Papillomavirus E2 trans-activation repressors

BIOGEN INC18 citations92

US5661004AAug 26, 1997

Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof

BIOGEN INC42 citations92

US5616559AApr 1, 1997

Papillomavirus E2 trans-activation repressors

BIOGEN INC23 citations92

US5272254ADec 21, 1993

Production of streptavidin-like polypeptides

BIOGEN INC21 citations92

US5047336ASep 10, 1991

DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides

BIOGEN INC26 citations92

US4956281ASep 11, 1990

DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3

BIOGEN INC108 citations92

Showing the top 50 of 125 patents by PatentIndex Score.

BIOGEN INC

Top patents by PatentIndex Score

Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA

Isolation of exogenous recombinant proteins from the milk of transgenic mammals

Genetically engineered plant cells and plants exhibiting resistance to glutamine synthetase inhibitors, DNA fragments and recombinants for use in the production of said cells and plants

Recombinant anti-VLA-4 antibody molecules

Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction

Tat-derived transport polypeptides and fusion proteins

Tat-derived transport polypeptide conjugates

Fusion protein comprising tat-derived transport moiety

Nucleic acid conjugates of tat-derived transport polypeptides

Treatment for inflammatory bowel disease with VLA-4 blockers

Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease

Soluble lymphotoxin-β receptor as a therapeutic agent for treating TH-1 cell-associated autoimmune disease

Treatment for inflammatory bowel disease with a vcam-1/1gG fusion protein

Soluble lymphotoxin-β receptors as therapeutic agents for the treatment of immunological disease

Treatment for insulin dependent diabetes

Treatment for asthma with VLA-4 blocking agents

Methods and compositions for inhibiting platelet aggregation

Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence

Papillomavirus e2 trans-activation repressors

CD2-binding domain of lymphocyte function associated antigen 3

Monoclonal antibodies against CDX

Production of streptavidin-like polypeptides

Nucleic acid probe linked to a label having a terminal cysteine

Antibodies to Ret and RetL3

Kidney injury-related molecules

Vascular cell adhesion molecule (VCAM) polypeptides

Muteins of IFN-β

Endothelial cell-leukocyte adhesion molecules (ELAMs) and molecules involved in leukocyte adhesion (MILAs)

DNA sequences encoding vascular cell adhesion molecules (VCAMS)

Inhibitors of thrombin

Processes for producing tumor necrosis factor

Inhibitors of thrombin

Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases

Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction

HBV core antigen particles with multiple immunogenic components attached via peptide ligands

Cell adhesion inhibitors

Common gamma chain monoclonal antibody blocking agents

Cell adhesion inhibitors

Method of using CD2-binding domain of lymphocyte function associated antigen 3 to initiate T cell activation

CD2-binding domain of lymphocyte function associated antigen-3

Anti-CD4 antibody homologs useful in prophylaxis and treatment of AIDS, ARC and HIV infection

Lymphotoxin-beta and lymphotoxin-beta complexes

Methods of inhibiting T-cell dependent proliferation of peripheral blood lymphocytes using the CD2-binding domain of lymphocyte function associated antigen 3

Lymphotoxin-β, Lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof

Papillomavirus E2 trans-activation repressors

Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof

Papillomavirus E2 trans-activation repressors

Production of streptavidin-like polypeptides

DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides

DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3